Clinical Trial Update: Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Open-label Phase 1 study evaluating BBO-8520 in adults with KRAS G12C-mutant non-small cell lung cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kras G12c-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• BBO-8520

Snippet

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Conditions: Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | Phase 1 | Status: RECRUITING